TY - JOUR
T1 - Ovarian Cancer, Version 3.2022 Featured Updates to the NCCN Guidelines
AU - Armstrong, Deborah K.
AU - Alvarez, Ronald D.
AU - Backes, Floor J.
AU - Bakkum-Gamez, Jamie N.
AU - Barroilhet, Lisa
AU - Behbakht, Kian
AU - Berchuck, Andrew
AU - Chen, Lee May
AU - Chitiyo, Viola C.
AU - Cristea, Mihaela
AU - DeRosa, Maria
AU - Eisenhauer, Eric L.
AU - Gershenson, David M.
AU - Gray, Heidi J.
AU - Grisham, Rachel
AU - Hakam, Ardeshir
AU - Jain, Angela
AU - Karam, Amer
AU - Konecny, Gottfried E.
AU - Leath, Charles A.
AU - Leiserowitz, Gary
AU - Liu, Joyce
AU - Martin, Lainie
AU - Matei, Daniela
AU - McHale, Michael
AU - McLean, Karen
AU - Miller, David S.
AU - Percac-Lima, Sanja
AU - Remmenga, Steven W.
AU - Schorge, John
AU - Stewart, Daphne
AU - Thaker, Premal H.
AU - Vargas, Roberto
AU - Hendrickson, Andrea Wahner
AU - Werner, Theresa L.
AU - Zsiros, Emese
AU - Dwyer, Mary A.
AU - Hang, Lisa
N1 - Publisher Copyright:
© 2022 Harborside Press. All rights reserved.
PY - 2022/9
Y1 - 2022/9
N2 - Epithelial ovarian cancer is the leading cause of death from gynecologic cancer in the United States, with less than half of patients living .5 years following diagnosis. The NCCN Guidelines for Ovarian Cancer provide recommendations for the diagnosis, evaluation, treatment, and follow-up for patients with ovarian, fallopian tube, and primary peritoneal cancers. These NCCN Guidelines Insights summarize the panel discussion behind recent important updates to the guidelines, including revised guidance on alternative chemotherapy regimens for patients with advanced age and/or comorbidities, a new algorithm for recurrent low-grade serous carcinoma based on developing research and novel therapeutic agents, and updated language regarding tumor molecular analysis applications in ovarian cancer.
AB - Epithelial ovarian cancer is the leading cause of death from gynecologic cancer in the United States, with less than half of patients living .5 years following diagnosis. The NCCN Guidelines for Ovarian Cancer provide recommendations for the diagnosis, evaluation, treatment, and follow-up for patients with ovarian, fallopian tube, and primary peritoneal cancers. These NCCN Guidelines Insights summarize the panel discussion behind recent important updates to the guidelines, including revised guidance on alternative chemotherapy regimens for patients with advanced age and/or comorbidities, a new algorithm for recurrent low-grade serous carcinoma based on developing research and novel therapeutic agents, and updated language regarding tumor molecular analysis applications in ovarian cancer.
UR - http://www.scopus.com/inward/record.url?scp=85137540169&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85137540169&partnerID=8YFLogxK
U2 - 10.6004/jnccn.2022.0047
DO - 10.6004/jnccn.2022.0047
M3 - Article
C2 - 36075393
AN - SCOPUS:85137540169
SN - 1540-1405
VL - 20
SP - 973
EP - 980
JO - JNCCN Journal of the National Comprehensive Cancer Network
JF - JNCCN Journal of the National Comprehensive Cancer Network
IS - 9
ER -